Xin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xin Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Bengang Hui
Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China
1 shared publicationBowei Qiao
Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China
1 shared publication- Fan Yang
Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China
1 shared publication - Han Zhang
Chest Hospital, Tianjin University, Tianjin 300072, China
1 shared publication Heng Zhao
Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China
1 shared publicationJiangnan Duan
Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China
1 shared publication
Latest Publications
- Open Access
Real-World Outcomes After Sublobar Resection for Small Node-Negative Lung Adenocarcinoma: SEER Benchmarking and a Clinicopathological Analysis
Background: Randomized trials support sublobar resection for selected small peripheral lung cancers, but real-world outcomes may vary by procedure type, nodal assessment, and pathological risk. Methods: We performed a two-stage real-world analysis. Stage 1 included 22,864 patients with lung adenocarcinoma ≤3 cm from a node-assessed N0M0 SEER cohort. Stage 2 included 872 patients with node-negative lung adenocarcinoma from a multi-institutional, single-center-dominant clinicopathological cohort. The primary endpoint was disease-free survival (DFS). Results: In SEER, sublobar resection was associated with higher all-cause mortality (HR 1.31, 95% CI 1.23–1.38) and lung cancer-specific death (HR 1.38, 95% CI 1.27–1.51). Procedure-specific estimates were smaller for segmentectomy than for wedge resection and were attenuated after adjustment for examined lymph-node count. In the clinicopathological cohort, the primary postoperative model showed a higher DFS hazard with sublobar resection (HR 1.75, 95% CI 1.08–2.83), with a similar estimate after overlap weighting (HR 1.75, 95% CI 1.08–2.85). However, the association was not statistically clear after propensity-score matching (HR 1.41, 95% CI 0.76–2.63), 60-month restriction (HR 1.09, 95% CI 0.58–2.03), or restriction to a comparable-follow-up cohort (HR 1.57, 95% CI 0.88–2.78). The proportional-hazards assumption for DFS was violated, and late estimates were based on sparse risk sets and were unstable. The recurrence association was predominantly locoregional, and increasing Core-HRPF burden was associated with progressively worse prognosis. Conclusions: Real-world sublobar resection is a heterogeneous exposure. Observed outcome associations varied by procedure type, nodal assessment, analytical specification, and follow-up horizon and should not be interpreted as evidence that sublobar resection is intrinsically inferior to lobectomy.
Open AccessReal-World Outcomes After Sublobar Resection for Small Node-Negative Lung Adenocarcinoma: SEER Benchmarking and a Clinicopathological Analysis
Background: Randomized trials support sublobar resection for selected small peripheral lung cancers, but real-world outcomes may vary by procedure type, nodal assessment, and pathological risk. Methods: We performed a two-stage real-world analysis. Stage 1 included 22,864 patients with lung adenocarcinoma ≤3 cm from a node-assessed N0M0 SEER cohort. Stage 2 included 872 patients with node-negative lung adenocarcinoma from a multi-institutional, single-center-dominant clinicopathological cohort. The primary endpoint was disease-free survival (DFS). Results: In SEER, sublobar resection was associated with higher all-cause mortality (HR 1.31, 95% CI 1.23–1.38) and lung cancer-specific death (HR 1.38, 95% CI 1.27–1.51). Procedure-specific estimates were smaller for segmentectomy than for wedge resection and were attenuated after adjustment for examined lymph-node count. In the clinicopathological cohort, the primary postoperative model showed a higher DFS hazard with sublobar resection (HR 1.75, 95% CI 1.08–2.83), with a similar estimate after overlap weighting (HR 1.75, 95% CI 1.08–2.85). However, the association was not statistically clear after propensity-score matching (HR 1.41, 95% CI 0.76–2.63), 60-month restriction (HR 1.09, 95% CI 0.58–2.03), or restriction to a comparable-follow-up cohort (HR 1.57, 95% CI 0.88–2.78). The proportional-hazards assumption for DFS was violated, and late estimates were based on sparse risk sets and were unstable. The recurrence association was predominantly locoregional, and increasing Core-HRPF burden was associated with progressively worse prognosis. Conclusions: Real-world sublobar resection is a heterogeneous exposure. Observed outcome associations varied by procedure type, nodal assessment, analytical specification, and follow-up horizon and should not be interpreted as evidence that sublobar resection is intrinsically inferior to lobectomy.
- Open Access
- 1 April 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (4) , 849-860
Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study
Background: Resectable non-small cell lung cancer (NSCLC) patients have a high risk of recurrence. Multiple randomized controlled trials (RCTs) have shown that neoadjuvant chemo-immunotherapy brings new hope for these patients. The study aims to evaluate the safety, surgery-related outcomes and oncological outcomes for neoadjuvant chemo-immunotherapy in real-world setting with a large sample size and long-term follow-up. Methods: Patients with clinical stage IB–IIIB NSCLC who received neoadjuvant chemo-immunotherapy at two Chinese institutions were included in this retrospective cohort study. Surgical and oncological outcomes of the enrolled NSCLC patients were collected and analyzed. Results: There were 158 patients identified, of which 124 (78.5%) were at stage IIIA–IIIB and the remaining 34 (21.5%) were at stage IB–IIB. Forty-one patients (25.9%) received two cycles of neoadjuvant treatment, 80 (50.6%) had three cycles, and 37 (23.4%) had four cycles. Twenty-four patients (15.2%) experienced grade 3 or worse immune-related adverse events. The median interval time between the last neoadjuvant therapy and surgery was 37 [interquartile range (IQR), 31–43] days. Fifty-eight out of 96 (60.4%) central NSCLC patients who were expected to undergo complex surgery had the scope or the difficulty of operation reduced. Ninety-five (60.1%) patients achieved major pathologic response (MPR), including 62 (39.2%) patients with pathologic complete response (pCR). Multivariate regression analysis showed that no clinical factor other than programmed death-ligand 1 (PD-L1) expression was predictive of the pathological response. The median follow-up time from diagnosis was 27.1 months. MPR and pCR were significantly associated with improved progression-free survival (PFS) and overall survival (OS). Neither stage nor PD-L1 expression was significantly associated with long-term survival. Conclusions: The neoadjuvant chemo-immunotherapy is a feasible strategy for NSCLC with a favorable rate of pCR/MPR, modified resection and 2-year survival. No clinical factor other than PD-L1 expression was predictive of the pathological response. pCR/MPR may be effective surrogate endpoint for survival in NSCLC patients who received neoadjuvant chemo-immunotherapy.
- 1 April 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (4) , 849-860
Open AccessEfficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study
Background: Resectable non-small cell lung cancer (NSCLC) patients have a high risk of recurrence. Multiple randomized controlled trials (RCTs) have shown that neoadjuvant chemo-immunotherapy brings new hope for these patients. The study aims to evaluate the safety, surgery-related outcomes and oncological outcomes for neoadjuvant chemo-immunotherapy in real-world setting with a large sample size and long-term follow-up. Methods: Patients with clinical stage IB–IIIB NSCLC who received neoadjuvant chemo-immunotherapy at two Chinese institutions were included in this retrospective cohort study. Surgical and oncological outcomes of the enrolled NSCLC patients were collected and analyzed. Results: There were 158 patients identified, of which 124 (78.5%) were at stage IIIA–IIIB and the remaining 34 (21.5%) were at stage IB–IIB. Forty-one patients (25.9%) received two cycles of neoadjuvant treatment, 80 (50.6%) had three cycles, and 37 (23.4%) had four cycles. Twenty-four patients (15.2%) experienced grade 3 or worse immune-related adverse events. The median interval time between the last neoadjuvant therapy and surgery was 37 [interquartile range (IQR), 31–43] days. Fifty-eight out of 96 (60.4%) central NSCLC patients who were expected to undergo complex surgery had the scope or the difficulty of operation reduced. Ninety-five (60.1%) patients achieved major pathologic response (MPR), including 62 (39.2%) patients with pathologic complete response (pCR). Multivariate regression analysis showed that no clinical factor other than programmed death-ligand 1 (PD-L1) expression was predictive of the pathological response. The median follow-up time from diagnosis was 27.1 months. MPR and pCR were significantly associated with improved progression-free survival (PFS) and overall survival (OS). Neither stage nor PD-L1 expression was significantly associated with long-term survival. Conclusions: The neoadjuvant chemo-immunotherapy is a feasible strategy for NSCLC with a favorable rate of pCR/MPR, modified resection and 2-year survival. No clinical factor other than PD-L1 expression was predictive of the pathological response. pCR/MPR may be effective surrogate endpoint for survival in NSCLC patients who received neoadjuvant chemo-immunotherapy.